SCHEMBL3852470

SCHEMBL3852470

CCN/C=C/N(CC)CC

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3852475 1.00
SCHEMBL23439640 0.77
SCHEMBL11472770 0.77
SCHEMBL11472772 0.77
SCHEMBL18897929 0.76
SCHEMBL446127 0.71
SCHEMBL2142076 0.71
SCHEMBL446126 0.71
SCHEMBL19886275 0.71
SCHEMBL3586589 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240279420-A1 POLYOL BLENDED LIQUID COMPOSITION FOR PRODUCTION OF HYDROCHLOROFLUOROOLEFIN BLOWN POLYURETHANE FOAM, AND ITS APPLICATION TOSOH CORPORATION (JP) 2024-08-22 US claimed
WO-2022239734-A1 POLYOL-BASED MIXED LIQUID COMPOSITION FOR PRODUCING HYDROCHLOROFUROOLEFIN FOAMED POLYURETHANE FOAM, AND USE THEREOF 東ソー株式会社 2022-11-17 WO claimed
US-20240279420-A1 POLYOL BLENDED LIQUID COMPOSITION FOR PRODUCTION OF HYDROCHLOROFLUOROOLEFIN BLOWN POLYURETHANE FOAM, AND ITS APPLICATION TOSOH CORPORATION (JP) 2024-08-22 US disclosed
WO-2022239734-A1 POLYOL-BASED MIXED LIQUID COMPOSITION FOR PRODUCING HYDROCHLOROFUROOLEFIN FOAMED POLYURETHANE FOAM, AND USE THEREOF 東ソー株式会社 2022-11-17 WO disclosed
EP-2087910-B1 Polymeric prodrugs ASCENDIS PHARMA GMBH (DE) 2022-05-04 EP disclosed
US-20210283264-A1 Polymeric Prodrugs with a Self-Immolative Linker ASCENDIS PHARMA GMBH (DE) 2021-09-16 US disclosed
EP-1732607-B1 POLYMERIC PRODRUG WITH A SELF-IMMOLATIVE LINKER ASCENDIS PHARMA GMBH (DE) 2019-05-15 EP disclosed
US-20160089448-A1 POLYMERIC PRODRUG WITH A SELF-IMMOLATIVE LINKER ASCENDIS PHARMA GMBH (DE) 2016-03-31 US disclosed
US-9238686-B2 Polymeric prodrug with self-immolative linker ASCENDIS PHARMA GMBH (DE) 2016-01-19 US disclosed
US-20130150281-A1 POLYMERIC PRODRUG WITH SELF-IMMOLATIVE LINKER ASCENDIS PHARMA GMBH (DE) 2013-06-13 US disclosed
US-8377917-B2 Polymeric prodrug with a self-immolative linker COMPLEX BIOSYSTEMS GMBH (DE) 2013-02-19 US disclosed
EP-2087910-A2 Polymeric prodrugs Complex Biosystems GmbH (DE) 2009-08-12 EP disclosed
US-20080241102-A1 Polymeric Prodrug with a Self-Immolative Linker COMPLEX BIOSYSTEMS GMBH (DE) 2008-10-02 US disclosed
US-7384952-B2 Pyrazolopyrimidine compound and a process for preparing the same MITSUBISHI TANABE PHARMA CORPORATION (JP) 2008-06-10 US disclosed
EP-1857459-A2 Pyrazolopyrimidine compound and a process for preparing the same TANABE SEIYAKU CO., LTD. (JP) 2007-11-21 EP disclosed
EP-1732607-A2 POLYMERIC PRODRUG WITH A SELF-IMMOLATIVE LINKER Complex Biosystems GmbH (DE) 2006-12-20 EP disclosed
US-20060135525-A1 Pyrazolopyrimidine compound and a process for preparing the same MITSUBISHI TANABE PHARMA CORPORATION (JP) 2006-06-22 US disclosed
EP-1625855-A1 Polymeric prodrug with a self-immolative linker Complex Biosystems GmbH (DE) 2006-02-15 EP disclosed
WO-2005099768-A2 POLYMERIC PRODRUG WITH A SELF-IMMOLATIVE LINKER COMPLEX BIOSYSTEMS GMBH (DE) 2005-10-27 WO disclosed